These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2666 related articles for article (PubMed ID: 8186429)

  • 1. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells.
    Lindström P; Olsson P; Malmqvist J; Pettersson J; Lemmen P; Werner B; Sjöberg S; Olin A; Carlsson J
    Anticancer Drugs; 1994 Feb; 5(1):43-52. PubMed ID: 8186429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron capture therapy.
    Liu L; Barth RF; Tjarks W; Soloway AH; Anisuzzaman AK
    Anticancer Res; 1996; 16(1):113-20. PubMed ID: 8615595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising carboranylquinazolines for boron neutron capture therapy: synthesis, characterization, and in vitro toxicity evaluation.
    Genady AR
    Eur J Med Chem; 2009 Jan; 44(1):409-16. PubMed ID: 18407378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of boron distribution in vivo for boron neutron capture therapy using two different boron compounds by secondary ion mass spectrometry.
    Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Okabe M; Kirihata M; Ono K; Kuroiwa T
    Radiat Res; 2007 Jan; 167(1):102-9. PubMed ID: 17214510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption.
    Barth RF; Yang W; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH; Soloway AH
    Cancer Res; 1997 Mar; 57(6):1129-36. PubMed ID: 9067283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
    Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy.
    Yong JH; Barth RF; Wyzlic IM; Soloway AH; Rotaru JH
    Anticancer Res; 1995; 15(5B):2033-8. PubMed ID: 8572598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 10B antitumoral compounds by means of flow-injection into ESI-MS/MS.
    Basilico F; Sauerwein W; Pozzi F; Wittig A; Moss R; Mauri PL
    J Mass Spectrom; 2005 Dec; 40(12):1546-9. PubMed ID: 16320299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficacy of the boron neutron capture agent DAC-1.
    Tilly N; Olsson P; Hartman T; Coderre J; Makar M; Malmquist J; Sjöberg S; Pettersson J; Carlsson J; Glimelius B
    Radiother Oncol; 1996 Jan; 38(1):41-50. PubMed ID: 8850425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro cytotoxicity of carboranyl amino acids, their chemical precursors and nido carboranyl amino acids for boron neutron capture therapy.
    Yong JH; Barth RF; Rotaru JH; Wyzlic IM; Soloway AH
    Anticancer Res; 1995; 15(5B):2039-43. PubMed ID: 8572599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced therapeutic effect on murine melanoma and angiosarcoma cells by boron neutron capture therapy using a boronated metalloporphyrin.
    Yamada Y; Toda K; Kahl SB; Ichihashi M
    Kobe J Med Sci; 1994 Feb; 40(1):25-37. PubMed ID: 8035560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
    Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
    Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of 10B in the central degenerative areas of human glioma and colon carcinoma spheroids after sulfhydryl boron hydride administration.
    Pettersson OA; Carlsson J; Grusell E
    Cancer Res; 1992 Mar; 52(6):1587-91. PubMed ID: 1540968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of boron-containing polyamines as potential agents for neutron capture therapy of brain tumors.
    Zhuo JC; Cai J; Soloway AH; Barth RF; Adams DM; Ji W; Tjarks W
    J Med Chem; 1999 Apr; 42(7):1282-92. PubMed ID: 10197971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closomers of high boron content: synthesis, characterization, and potential application as unimolecular nanoparticle delivery vehicles for boron neutron capture therapy.
    Ma L; Hamdi J; Wong F; Hawthorne MF
    Inorg Chem; 2006 Jan; 45(1):278-85. PubMed ID: 16390066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular distribution of various boron compounds and implications for their efficacy in boron neutron capture therapy by Monte Carlo simulations.
    Nguyen T; Brownell GL; Holden SA; Kahl S; Miura M; Teicher BA
    Radiat Res; 1993 Jan; 133(1):33-40. PubMed ID: 8434111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S; Sakurai Y; Suzuki M; Nagata K; Maruhashi A; Kinash Y; Ono K
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):920-7. PubMed ID: 15465210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake, toxicity and radiation effects of the boron compounds DAAC-1 and DAC-1 in cultured human glioma cells.
    Olsson P; Black M; Capala J; Coderre J; Hartman T; Makar M; Malmquist J; Pettersson J; Tilly N; Sjöberg S; Carlsson J
    Int J Radiat Biol; 1998 Jan; 73(1):103-12. PubMed ID: 9464482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake and distribution of the boron-containing ether lipid B-Et-11-OMe in tumor-bearing mice.
    Lemmen P; Weissfloch L; Auberger T; Probst T
    Anticancer Drugs; 1995 Dec; 6(6):744-8. PubMed ID: 8845486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy.
    Byun Y; Yan J; Al-Madhoun AS; Johnsamuel J; Yang W; Barth RF; Eriksson S; Tjarks W
    J Med Chem; 2005 Feb; 48(4):1188-98. PubMed ID: 15715485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 134.